Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints

A standardized multidisciplinary approach reduces the use of allogeneic blood products in patients undergoing cardiac surgery

“…20,21 However, this drug is associated with several side effects that should be taken into account. 22,23 Aprotinin was administered in about 50% of patients, using the Hammersmith regimen as it appears to be the most effective and also the safer one.…”

Hospital economic impact from hemostatic matrix usage in cardiac surgery

“…Excessive blood loss and allogeneic blood transfusions during or after surgery are associated with increased morbidity and mortality [1][2][3][4] . Patients experiencing bleeding-related complications including bleeding events, re-operation to control bleeding, and/or transfusion of blood products, require an increased hospital length of stay and longer ICU time resulting in an increased economic burden relative to patients without these events 5 .…”

Management of May–Hegglin anomaly referred for coronary artery bypass

“…The haemostatic agents are frequently used in surgery to reduce the blood loss and the transfusion requirements. The treatment with lysine analogues like tranexamic acid that was used in our patient has been shown to reduce the bleeding after cardiopulmonary bypass by 30-40% [4,5]. The use of aprotinin has also been shown to reduce the blood transfusion requirements.…”

“…The use of aprotinin has also been shown to reduce the blood transfusion requirements. Unlike tranexamic acid and aprotinin, the use of desmopressin resulted in a small decrease in the perioperative blood loss and was associated with an increased risk of myocardial infarction [4,5]. The anaesthetic drugs may also have an impact on the hemostasis.…”